Search

Abstract Background Despite the proven efficacy and safety of apremilast to treat plaque psoriasis (PsO), data regarding its real‐world use and patient‐perceived benefits are limited. Objectives Describe apremilast use, persistence and tolerability, and its patient‐perceived benefits and effectiveness in patients with PsO in Spanish clinical practice. Methods Observational, prospective, multicenter study including patients with moderate‐to‐severe PsO initiating apremilast 3 months (±4 weeks) before enrolment, after at least one conventional systemic therapy and no biologics. Prospective data were collected 3 (at enrolment), 6 and 12 months (±4 weeks) after apremilast initiation. Primary outcome was a Patient Benefit Index (PBI) score ≥1 (minimum clinically relevant benefit) at 6 months. Results Of 153 patients enroled, 119 were included in the analysis; mean (standard deviation [SD]) age, 52.8 (15.2) years. At apremilast initiation, mean (SD) Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) were 8.3 (4.9) and 10.5 (6.8), respectively. Most patients (81%) had comorbidities; PsO manifestations included scalp (47% of patients), palmoplantar (26%), nails (24%) and genitals (11%). Over three‐quarters (86%) of patients were continuing apremilast at Month 6, with most (91%) achieving a PBI ≥ 1% and 43% achieving a PBI ≥ 3; two‐thirds (68%) were continuing apremilast at Month 12, with 91% and 42% achieving a PBI ≥ 1 and ≥3, respectively. Mean (SD) pruritus scores decreased from 54.5 (32.1) at apremilast initiation to 23.4 (27.0) at Month 12; 57%, 69% and 69% of patients achieved a DLQI 0‒1, PASI

Introduction. Pityriasis lichenoides is a rare, acquired spectrum of skin conditions of an unknown etiology. Case Report. A 28-year-old man presented with recurrent outbreaks of herpes simplex virus associated with the onset of red-to-brown maculopapules located predominantly in trunk in each recurrence. Positive serologies to herpes simplex virus type 2 were detected. Histopathological examination of one of the lesions was consistent with a diagnosis of pityriasis lichenoides chronica. Discussion. Pityriasis lichenoides is a rare cutaneous entity of an unknown cause which includes different clinical presentations. A number of infectious agents have been implicated based on the clustering of multiple outbreaks and elevated serum titers to specific pathogens (human immunodeficiency virus, cytomegalovirus, Epstein-Barr virus, Toxoplasma gondii, and herpes simplex virus). In our patient, resolution of cutaneous lesions coincided with the administration of antiviral drugs and clinical improvement in each genital herpes recurrence. In conclusion, we report a case in which cutaneous lesions of pityriasis lichenoides chronica and a herpes simplex virus-type 2-mediated disease have evolved concomitantly.

Introduction. Pityriasis lichenoides is a rare, acquired spectrum of skin conditions of an unknown etiology. Case Report. A 28-year-old man presented with recurrent outbreaks of herpes simplex virus associated with the onset of red-to-brown maculopapules located predominantly in trunk in each recurrence. Positive serologies to herpes simplex virus type 2 were detected. Histopathological examination of one of the lesions was consistent with a diagnosis of pityriasis lichenoides chronica. Discussion. Pityriasis lichenoides is a rare cutaneous entity of an unknown cause which includes different clinical presentations. A number of infectious agents have been implicated based on the clustering of multiple outbreaks and elevated serum titers to specific pathogens (human immunodeficiency virus, cytomegalovirus, Epstein-Barr virus, Toxoplasma gondii, and herpes simplex virus). In our patient, resolution of cutaneous lesions coincided with the administration of antiviral drugs and clinical improvement in each genital herpes recurrence. In conclusion, we report a case in which cutaneous lesions of pityriasis lichenoides chronica and a herpes simplex virus-type 2-mediated disease have evolved concomitantly. [ABSTRACT FROM AUTHOR]